Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

IκB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1.

Koppe C, Verheugd P, Gautheron J, Reisinger F, Kreggenwinkel K, Roderburg C, Quagliata L, Terracciano L, Gassler N, Tolba RH, Boege Y, Weber A, Karin M, Luedde M, Neumann UP, Weiskirchen R, Tacke F, Vucur M, Trautwein C, Lüscher B, Preisinger C, Heikenwalder M, Luedde T.

Hepatology. 2016 Oct;64(4):1217-31. doi: 10.1002/hep.28723. Epub 2016 Aug 11.

PMID:
27396433
2.

Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.

Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L.

Hepatology. 2016 Mar;63(3):864-79. doi: 10.1002/hep.28367. Epub 2016 Jan 14.

3.

Hepatic tissue environment in NEMO-deficient mice critically regulates positive selection of donor cells after hepatocyte transplantation.

Kaldenbach M, Cubero FJ, Erschfeld S, Liedtke C, Trautwein C, Streetz K.

PLoS One. 2014 Jun 30;9(6):e100786. doi: 10.1371/journal.pone.0100786. eCollection 2014.

4.

Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression.

Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, Latte G, Calvisi DF, Seddaiu MA, Daino L, Feo CF, Brozzetti S, Solinas G, Yamashita S, Ushijima T, Feo F, Pascale RM.

Hepatology. 2012 Jul;56(1):165-75. doi: 10.1002/hep.25643. Epub 2012 Jun 5.

PMID:
22318685
5.

[Inhibitory effect of 4-chlorobenzoyl berbamine on imatinib-resistant K562 cells in vitro and in vivo].

Zhang YF, Xu GB, Gan YC, Xu XH, Xu RZ.

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Dec;31(12):1997-2001. Chinese.

PMID:
22200699
6.

IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression.

Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, Dhar D, Karin M, Chen CH, Hung MC.

Mol Cell. 2012 Jan 27;45(2):171-84. doi: 10.1016/j.molcel.2011.11.018. Epub 2011 Dec 22.

7.

The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer.

Liedtke C, Trautwein C.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):582-9. doi: 10.1016/j.ejcb.2011.10.001. Epub 2011 Dec 6. Review.

PMID:
22153863
8.

TAK1: Another mesh in the NF-κB - JNK controlled network causing hepatocellular carcinoma.

Greten FR.

J Hepatol. 2011 Sep;55(3):721-723. doi: 10.1016/j.jhep.2011.02.037. Epub 2011 May 10.

9.

Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice.

Koh SJ, Kim JM, Kim IK, Kim N, Jung HC, Song IS, Kim JS.

Am J Physiol Gastrointest Liver Physiol. 2011 Jul;301(1):G9-19. doi: 10.1152/ajpgi.00267.2010. Epub 2011 Mar 24.

10.

Hepatocyte-specific activation of NF-kappaB does not aggravate chemical hepatocarcinogenesis in transgenic mice.

Yau TO, Chan CF, Gee-San Lam S, Cheung OF, Ching YP, Jin DY, Sham MH, Ng IO.

J Pathol. 2009 Feb;217(3):353-61. doi: 10.1002/path.2451.

PMID:
19090486
11.

Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.

Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Sakamaki T, Pestell RG, Yamamoto K.

Clin Cancer Res. 2007 Apr 1;13(7):2236-45.

12.

Tracking the road from inflammation to cancer: the critical role of IkappaB kinase (IKK).

Karin M.

Harvey Lect. 2006-2007;102:133-51. Review. No abstract available.

PMID:
20166567
13.
14.

Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis.

Cavin LG, Venkatraman M, Factor VM, Kaur S, Schroeder I, Mercurio F, Beg AA, Thorgeirsson SS, Arsura M.

Cancer Res. 2004 Oct 1;64(19):7030-8.

15.

The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10386-91. Epub 2001 Aug 21.

Supplemental Content

Loading ...
Support Center